Shares of Quick Heal Technologies Ltd. surged by 3.49 percent to Rs 214.80 in Wednesday's trade, extending a remarkable rally that has seen the stock gain 26.35 percent over the last five trading sessions. This upward momentum follows an announcement that ace investor Vijay Kedia's office acquired a stake in the debt-free IT company through a bulk deal.
Quick Heal Under Surveillance Amid Volatility
Amid the heightened price action and significant trading volume, both the BSE and NSE have placed Quick Heal Technologies under the short-term Additional Surveillance Measure (ASM) framework. Exchanges typically implement ASM to alert investors to unusual price movements and to curb excessive speculation, signaling increased scrutiny on the stock's trading activity.
Kedia Securities' Bulk Deal Details
According to data from Trendlyne, Kedia Securities Pvt Ltd, representing Vijay Kedia's investment office, purchased approximately 4.5 lakh shares of Quick Heal Technologies. The transaction occurred on May 8 at a price of Rs 209.13 per share, amounting to a total deal size of nearly Rs 9.41 crore. This significant acquisition appears to have fueled investor confidence and contributed to the recent surge.
As of the latest report, the company commands a market capitalization of Rs 1,163.34 crore. Promoter holding in the debt-free IT firm stood at 71.50 percent as of March 2026, indicating strong insider confidence.
Technical Indicators and Financial Snapshot
Technically, Quick Heal Technologies' stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, and 100-day simple moving averages (SMAs), suggesting a strong short-to-medium term uptrend. However, it remains below its 150-day and 200-day SMAs, indicating some longer-term resistance. The 14-day Relative Strength Index (RSI) is currently at 74.87, placing the stock in overbought territory and potentially signaling a short-term correction.
Financially, the company trades at a standalone/consolidated price-to-earnings (P/E) ratio of 171.24/462.60 and a price-to-book (P/B) value of 2.66. It reported earnings per share (EPS) of 1.25/0.46 and a return on equity (RoE) of 1.56. The stock's one-year beta of 1.84 suggests relatively high volatility compared to the broader market.